Review of experimental compounds demonstrating anti-Toxoplasma activity

Madalyn M. McFarland, Sydney J. Zach, Xiaofang Wang, Lakshmi Prasad Potluri, Andrew J. Neville, Jonathan L. Vennerstrom, Paul H. Davis

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Toxoplasma gondii is a ubiquitous apicomplexan parasite capable of infecting humans and other animals. Current treatment options for T. gondii infection are limited and most have drawbacks, including high toxicity and low tolerability. Additionally, no FDA-approved treatments are available for pregnant women, a high-risk population due to transplacental infection. Therefore, the development of novel treatment options is needed. To aid this effort, this review highlights experimental compounds that, at a minimum, demonstrate inhibition of in vitro growth of T. gondii. When available, host cell toxicity and in vivo data are also discussed. The purpose of this review is to facilitate additional development of anti-Toxoplasma compounds and potentially to extend our knowledge of the parasite.

Original languageEnglish (US)
Pages (from-to)7017-7034
Number of pages18
JournalAntimicrobial Agents and Chemotherapy
Volume60
Issue number12
DOIs
StatePublished - Dec 2016

Fingerprint

Toxoplasma
Parasites
Toxoplasmosis
Pregnant Women
Therapeutics
Growth
Infection
Population

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Review of experimental compounds demonstrating anti-Toxoplasma activity. / McFarland, Madalyn M.; Zach, Sydney J.; Wang, Xiaofang; Potluri, Lakshmi Prasad; Neville, Andrew J.; Vennerstrom, Jonathan L.; Davis, Paul H.

In: Antimicrobial Agents and Chemotherapy, Vol. 60, No. 12, 12.2016, p. 7017-7034.

Research output: Contribution to journalReview article

McFarland, Madalyn M. ; Zach, Sydney J. ; Wang, Xiaofang ; Potluri, Lakshmi Prasad ; Neville, Andrew J. ; Vennerstrom, Jonathan L. ; Davis, Paul H. / Review of experimental compounds demonstrating anti-Toxoplasma activity. In: Antimicrobial Agents and Chemotherapy. 2016 ; Vol. 60, No. 12. pp. 7017-7034.
@article{3b2003526360466b85740c8af090923d,
title = "Review of experimental compounds demonstrating anti-Toxoplasma activity",
abstract = "Toxoplasma gondii is a ubiquitous apicomplexan parasite capable of infecting humans and other animals. Current treatment options for T. gondii infection are limited and most have drawbacks, including high toxicity and low tolerability. Additionally, no FDA-approved treatments are available for pregnant women, a high-risk population due to transplacental infection. Therefore, the development of novel treatment options is needed. To aid this effort, this review highlights experimental compounds that, at a minimum, demonstrate inhibition of in vitro growth of T. gondii. When available, host cell toxicity and in vivo data are also discussed. The purpose of this review is to facilitate additional development of anti-Toxoplasma compounds and potentially to extend our knowledge of the parasite.",
author = "McFarland, {Madalyn M.} and Zach, {Sydney J.} and Xiaofang Wang and Potluri, {Lakshmi Prasad} and Neville, {Andrew J.} and Vennerstrom, {Jonathan L.} and Davis, {Paul H.}",
year = "2016",
month = "12",
doi = "10.1128/AAC.01176-16",
language = "English (US)",
volume = "60",
pages = "7017--7034",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Review of experimental compounds demonstrating anti-Toxoplasma activity

AU - McFarland, Madalyn M.

AU - Zach, Sydney J.

AU - Wang, Xiaofang

AU - Potluri, Lakshmi Prasad

AU - Neville, Andrew J.

AU - Vennerstrom, Jonathan L.

AU - Davis, Paul H.

PY - 2016/12

Y1 - 2016/12

N2 - Toxoplasma gondii is a ubiquitous apicomplexan parasite capable of infecting humans and other animals. Current treatment options for T. gondii infection are limited and most have drawbacks, including high toxicity and low tolerability. Additionally, no FDA-approved treatments are available for pregnant women, a high-risk population due to transplacental infection. Therefore, the development of novel treatment options is needed. To aid this effort, this review highlights experimental compounds that, at a minimum, demonstrate inhibition of in vitro growth of T. gondii. When available, host cell toxicity and in vivo data are also discussed. The purpose of this review is to facilitate additional development of anti-Toxoplasma compounds and potentially to extend our knowledge of the parasite.

AB - Toxoplasma gondii is a ubiquitous apicomplexan parasite capable of infecting humans and other animals. Current treatment options for T. gondii infection are limited and most have drawbacks, including high toxicity and low tolerability. Additionally, no FDA-approved treatments are available for pregnant women, a high-risk population due to transplacental infection. Therefore, the development of novel treatment options is needed. To aid this effort, this review highlights experimental compounds that, at a minimum, demonstrate inhibition of in vitro growth of T. gondii. When available, host cell toxicity and in vivo data are also discussed. The purpose of this review is to facilitate additional development of anti-Toxoplasma compounds and potentially to extend our knowledge of the parasite.

UR - http://www.scopus.com/inward/record.url?scp=84996560082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996560082&partnerID=8YFLogxK

U2 - 10.1128/AAC.01176-16

DO - 10.1128/AAC.01176-16

M3 - Review article

C2 - 27600037

AN - SCOPUS:84996560082

VL - 60

SP - 7017

EP - 7034

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 12

ER -